<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;N02C&quot;,&quot;href&quot;:&quot;atc/N02C.md&quot;},{&quot;label&quot;:&quot;sumatriptan&quot;}]"></div>
<div class="pk-recnav" data-items="[{&quot;id&quot;:&quot;Sumatriptan_Cosson1999_reference&quot;,&quot;label&quot;:&quot;Cosson_1999_reference&quot;,&quot;group&quot;:&quot;popPK&quot;,&quot;href&quot;:&quot;drugs/drug_sumatriptan/Sumatriptan_Cosson1999_reference.md&quot;,&quot;status&quot;:&quot;needs review&quot;,&quot;css&quot;:&quot;pk-badge--orange&quot;,&quot;here&quot;:false}]"></div>

# sumatriptan

- **generic name:** sumatriptan
- **ATC codes:** `N02CC01`, `N02CC51`
- **DrugBank:** [DB00669](https://go.drugbank.com/drugs/DB00669) · **PubChem:** [CID 5358](https://pubchem.ncbi.nlm.nih.gov/compound/5358)
- **molar mass:** 295.4 g/mol (C14H21N3O2S) — DrugBank
- **groups:** approved, investigational

## About

Sumatriptan is a serotonin 5-HT1 receptor agonist used to treat migraine, including migraine with or without aura, and has also been used for giant cell arteritis. It is an approved antimigraine medicine, widely used, with products authorised across the European Union.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q416978](https://www.wikidata.org/wiki/Q416978) and the WHO ATC classification and the EMA medicines list; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-01 22:16 | 1:36 | 0/2/2 | 0/2/0 | 0/0/0 | 24,947/3,838 | ollama / qwen3.8:27b-mtp-q8_0 | 11 | 3/8 | 10/1 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.444). The first reading is what the record holds.">cross-check: partial</span><br><sub>blocking: C6_cl_magnitude failed (ratio None)</sub><br><sub>route_to: `human_review`</sub> | [Christensen_2004_reference](drugs/drug_sumatriptan/Sumatriptan_Christensen2004_reference.md) | — | 1-compartment (no model) | 5 | Christensen ML et al., Pharmacokinetics of sumatriptan nasal s…, Journal of clinical pharmac… (2004) | [10.1177/0091270004263467](https://doi.org/10.1177/0091270004263467) |
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (partly confirmed, agreement 0.667). The first reading is what the record holds.">cross-check: partial</span><br><sub>blocking: disposition incomplete — only clearance/elimination extracted — the engineer ne…</sub><br><sub>route_to: `human_review`</sub> | [Cosson_1999_reference](drugs/drug_sumatriptan/Sumatriptan_Cosson1999_reference.md) | ▶ model + simulator | 1-compartment, IV | 2 | Cosson VF et al., Mixed effect modeling of sumatriptan ph…, Journal of pharmacokinetics… (1999) | [10.1023/a:1020601906027](https://doi.org/10.1023/a:1020601906027) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.333). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: C5 dimension mismatch on a structural parameter</sub><br><sub>route_to: `human_review`</sub> | [Christensen_2003_reference](drugs/drug_sumatriptan/Sumatriptan_Christensen2003_reference.md) | — | 1-compartment (no model) | 5 | Christensen ML et al., Pharmacokinetics of sumatriptan nasal s…, Journal of clinical pharmac… (2003) | — |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--green" title="re-read by gpt-oss:120b (confirmed, agreement 1.0). The first reading is what the record holds.">cross-checked ✓</span><br><sub>blocking: no structural parameters extracted (nothing to build)</sub><br><sub>route_to: `human_review`</sub> | [Ohk_2022_reference](drugs/drug_sumatriptan/Sumatriptan_Ohk2022_reference.md) | — | 1-compartment (no model) | 0 | Ohk B et al., Evaluation of sex differences in the ph…, Biopharmaceutics & drug dis… (2022) | [10.1002/bdd.2307](https://doi.org/10.1002/bdd.2307) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">in vitro</span> | [Longmore_1996_isometric_tension](drugs/drug_sumatriptan/pd_Longmore_1996_isometric_tension.md) | name ← rizatriptan · direct Emax (saturable) effect | — | Longmore J et al., 5-HT1D receptor agonists and human coro…, British journal of clinical… (1996) | [10.1046/j.1365-2125.1996.04217.x](https://doi.org/10.1046/j.1365-2125.1996.04217.x) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--orange" title="re-read by gpt-oss:120b (?, agreement 0.0). The first reading is what the record holds.">cross-check: partial</span> <span class="pk-badge pk-badge--species" title="In-vitro data (cells, tissue or microsomes), not measured in people (from an LLM reading of the title and abstract by gpt-6-luna, p(non-human) 1.00).">in vitro</span> | [MaassenVanDenBrink_1998_unknown](drugs/drug_sumatriptan/pd_MaassenVanDenBrink_1998_unknown.md) | coronary artery contraction ← unknown · direct Emax (saturable) effect | — | MaassenVanDenBrink A et al., Coronary side-effect potential of curre…, Circulation (1998) | [10.1161/01.cir.98.1.25](https://doi.org/10.1161/01.cir.98.1.25) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=sumatriptan) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | blood-brain barrier | `ABCB1` substrate, `ABCG2` substrate, `SLCO1A2` inducer | DrugBank actor |
| absorption | kidney | `ABCB1` substrate | DrugBank actor |
| absorption | liver | `ABCB1` substrate, `ABCG2` substrate | DrugBank actor |
| absorption | mammary gland | `ABCG2` substrate | DrugBank actor |
| absorption | placenta | `ABCB1` substrate | DrugBank actor |
| absorption | small intestine | `ABCB1` substrate, `ABCG2` substrate, `SLCO1A2` inducer | DrugBank actor |
| absorption | testis | `ABCB1` substrate, `ABCG2` substrate | DrugBank actor |
| metabolism | brain | `MAOA` substrate | DrugBank actor |
| metabolism | liver | `MAOA` substrate, `SLCO1B1` substrate | DrugBank actor |
| metabolism | small intestine | `MAOA` substrate | DrugBank actor |
| excretion | bile duct | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: HTR1A (target), HTR1B (target), HTR1D (target), HTR1F (target).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 133 matched, 56 returned
- **screened:** 12  ·  **relevant:** 4
- **records:** 4  ·  extracted 0  ·  needs_review 2  ·  rejected 2  ·  stale 0
- **scholar-agent fallback query used:** not captured

## Full text wanted

_14 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Christensen_2003.pdf` | Christensen ML et al., Pharmacokinetics of sumatriptan nasal s…, Journal of clinical pharmac… (2003) | popPK | 10 | not captured | [12856385](https://pubmed.ncbi.nlm.nih.gov/12856385) | The evidence explicitly reports quantitative population PK parameters (CL/F, Vd/F) and non-compartmental parameters (Cmax, AUC, t1/2) for sumatriptan. |
| `Christensen_2004.pdf` | Christensen ML et al., Pharmacokinetics of sumatriptan nasal s…, Journal of clinical pharmac… (2004) | popPK | 10 | [10.1177/0091270004263467](https://doi.org/10.1177/0091270004263467) | [15051742](https://pubmed.ncbi.nlm.nih.gov/15051742) | The paper reports quantitative population PK parameters (CL/F, V, half-life) for sumatriptan in children with specific numeric values provided in the text. |
| `Cosson_1999.pdf` | Cosson VF et al., Mixed effect modeling of sumatriptan ph…, Journal of pharmacokinetics… (1999) | popPK | 10 | [10.1023/a:1020601906027](https://doi.org/10.1023/a:1020601906027) | [10567953](https://pubmed.ncbi.nlm.nih.gov/10567953) | The paper reports a population PK model for sumatriptan with specific numeric values for clearance (71.2 L/hr, 68.7 L/hr) and volume of distribution (94.5 L, 109 L) directly in the text. |
| `Ohk_2022.pdf` | Ohk B et al., Evaluation of sex differences in the ph…, Biopharmaceutics & drug dis… (2022) | popPK | 10 | [10.1002/bdd.2307](https://doi.org/10.1002/bdd.2307) | [34923646](https://pubmed.ncbi.nlm.nih.gov/34923646) | The study is a population PK analysis of sumatriptan and explicitly reports quantitative clearance values for males and females in the text. |
| `Fox_2010.pdf` | Fox AW, Subcutaneous sumatriptan pharmacokineti…, Headache (2010) | popPK | 8 | [10.1111/j.1526-4610.2009.01568.x](https://doi.org/10.1111/j.1526-4610.2009.01568.x) | [19925626](https://pubmed.ncbi.nlm.nih.gov/19925626) | The paper describes a compartmental PK model for sumatriptan and reports specific AUC and concentration values, but lacks explicit numeric values for core disposition parameters like clearance (CL), volume (V), or rate constants (ka, ke). |
| `Fullerton_1999.pdf` | Fullerton T et al., The pharmacodynamics of sumatriptan in…, Journal of clinical pharmac… (1999) | popPK | 8 | [10.1177/00912709922007525](https://doi.org/10.1177/00912709922007525) | [9987697](https://pubmed.ncbi.nlm.nih.gov/9987697) | The study fits a two-compartment PK model for sumatriptan, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence. |
| `Maas_2006.pdf` | Maas HJ et al., Prediction of headache response in migr…, Cephalalgia : an internatio… (2006) | popPK | 8 | [10.1111/j.1468-2982.2005.01050.x](https://doi.org/10.1111/j.1468-2982.2005.01050.x) | [16556242](https://pubmed.ncbi.nlm.nih.gov/16556242) | The paper describes a population PK/PD model for sumatriptan, but the specific numeric PK parameter values (CL, V, etc.) are not present in the provided evidence, only the EC50. |
| `Maas_2008.pdf` | Maas HJ et al., Relevance of absorption rate and lag ti…, Clinical pharmacokinetics (2008) | popPK | 8 | [10.2165/00003088-200847020-00007](https://doi.org/10.2165/00003088-200847020-00007) | [18193920](https://pubmed.ncbi.nlm.nih.gov/18193920) | The paper describes a population PK model for sumatriptan and reports specific absorption parameters (lag time 0.24 h), but lacks other core disposition parameters like clearance or volume. |
| `McConnachie_2023.pdf` | McConnachie L et al., New characterization of dihydroergotami…, Frontiers in neurology (2023) | pd | 4 | [10.3389/fneur.2023.1282846](https://doi.org/10.3389/fneur.2023.1282846) | [38073648](https://www.ncbi.nlm.nih.gov/pubmed/38073648) | metadata signals extractable PD data (IC50) |
| `Gilibili_2026.pdf` | Gilibili RR et al., Investigating organic cation transporte…, Drug metabolism and disposi… (2026) | pgx | 8 | [10.1016/j.dmd.2025.100220](https://doi.org/10.1016/j.dmd.2025.100220) | [41529637](https://www.ncbi.nlm.nih.gov/pubmed/41529637) | metadata signals extractable PGX data (SLC22A1, PK/PD-context) |
| `Kashihara_2017.pdf` | Kashihara Y et al., Small-Dosing Clinical Study: Pharmacoki…, Journal of pharmaceutical s… (2017) | pgx | 8 | [10.1016/j.xphs.2017.03.010](https://doi.org/10.1016/j.xphs.2017.03.010) | [28322941](https://www.ncbi.nlm.nih.gov/pubmed/28322941) | metadata signals extractable PGX data (ABCG2, PK/PD-context) |
| `Morse_2020.pdf` | Morse BL et al., Pharmacokinetics of Organic Cation Tran…, Drug metabolism and disposi… (2020) | pgx | 8 | [10.1124/dmd.119.088781](https://doi.org/10.1124/dmd.119.088781) | [31771949](https://www.ncbi.nlm.nih.gov/pubmed/31771949) | metadata signals extractable PGX data (SLC22A1, PK/PD-context) |
| `Varma_2023.pdf` | Varma MVS, Genetic variation in organic cation tra…, Expert opinion on drug meta… (2023) | pgx | 8 | [10.1080/17425255.2023.2202813](https://doi.org/10.1080/17425255.2023.2202813) | [37070463](https://www.ncbi.nlm.nih.gov/pubmed/37070463) | metadata signals extractable PGX data (SLC47A1, PK/PD-context) |
| `Moore_2002.pdf` | Moore KH et al., The pharmacokinetics of sumatriptan whe…, Clinical therapeutics (2002) | pgx | 7 | [10.1016/s0149-2918(02)85134-7](https://doi.org/10.1016/s0149-2918(02)85134-7) | [12017403](https://www.ncbi.nlm.nih.gov/pubmed/12017403) | metadata signals extractable PGX data (CYP3A4, PK/PD-context) |

<sub>queue written 2026-09-21T07:41:05.614612+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | Bax_1993 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of receptor-mediated contractions in isolated human coronary arteries, not a pharmacokinetic study reporting disposition parameters for sumatriptan. |
| PGx | Bokelmann_2018 | not_relevant | 0 | 0 | The study explicitly states that the analyzed OCT1 promoter SNPs were not associated with the pharmacokinetics of sumatriptan. |
| PGx | Capi_2016 | not_relevant | 0 | 0 | The paper reviews eletriptan, not sumatriptan, and discusses drug-drug interactions (CYP3A4) rather than pharmacogenomic effects of genetic variants. |
| popPK | Comisar_2025 | irrelevant | 0 | 0 | The study focuses on the pharmacokinetics of zavegepant, with sumatriptan mentioned only as a co-administered drug that did not significantly affect zavegepant's PK. |
| PGx | Fiszman_2006 | not_relevant | 0 | 0 | The paper describes a methodology for automatic summarization of drug information in Medline citations and does not report specific pharmacogenomic effects on sumatriptan PK/PD parameters. |
| popPK | Fox_2010 | relevant | 8 | 3 | The paper describes a compartmental PK model for sumatriptan and reports specific AUC and concentration values, but lacks explicit numeric values for core disposition parameters like clearance (CL), volume (V), or rate constants (ka, ke). |
| popPK | Fullerton_1999 | relevant | 8 | 0 | The study fits a two-compartment PK model for sumatriptan, but the specific numeric parameter values (CL, V, etc.) are not present in the provided evidence. |
| PGx | Gilibili_2026 | not_relevant | 0 | 0 | The study investigates drug-drug interactions mediated by OCT1 in cynomolgus monkeys, not the effect of human genetic variants (pharmacogenomics) on sumatriptan pharmacokinetics. |
| PGx | Grände_2014 | not_relevant | 0 | 0 | The paper investigates the pharmacodynamic effects of sumatriptan on isolated arteries but does not report any association with genetic variants or genotypes. |
| popPK | Gul_2002 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of vascular contraction, not a pharmacokinetic study, and reports no disposition parameters. |
| popPK | Heblinski_2019 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of receptor desensitization and reports pharmacodynamic parameters (EC50), not pharmacokinetic disposition parameters. |
| PGx | Jehangir_2024 | not_relevant | 0 | 0 | The paper investigates bacterial biotransformation of sumatriptan, not human pharmacogenomics. |
| PGx | Jensen_2021 | not_relevant | 0 | 0 | The paper investigates isobutyrylcarnitine as a biomarker for OCT1 activity and does not report pharmacogenomic effects on the pharmacokinetic or pharmacodynamic parameters of sumatriptan. |
| PGx | Kashihara_2017 | not_relevant | 5 | 2 | The study reports that SLCO2B1*3 had no effect on sumatriptan PK and does not report ABCG2 effects on sumatriptan, only on sulfasalazine and rosuvastatin. |
| PGx | Kölz_2021 | not_relevant | 2 | 0 | The paper is a general review of OCT genetics and epigenetics; it mentions sumatriptan only as an example of a substrate but does not report specific pharmacogenomic effects on its PK or PD parameters. |
| popPK | Longmore_1996 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of coronary artery contraction, not a pharmacokinetic study, and sumatriptan is used only as a comparator agent. |
| popPK | Maas_2006 | relevant | 8 | 2 | The paper describes a population PK/PD model for sumatriptan, but the specific numeric PK parameter values (CL, V, etc.) are not present in the provided evidence, only the EC50. |
| popPK | Maas_2006_2 | irrelevant | 0 | 0 | The study focuses on pharmacodynamic modeling (efficacy, EC50, Emax) of sumatriptan versus naratriptan and does not report pharmacokinetic disposition parameters. |
| popPK | Maas_2008 | relevant | 8 | 2 | The paper describes a population PK model for sumatriptan and reports specific absorption parameters (lag time 0.24 h), but lacks other core disposition parameters like clearance or volume. |
| popPK | MaassenVanDenBrink_1998 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of coronary artery contraction (EC50/Emax) and does not report pharmacokinetic disposition parameters (CL, V, ka) for sumatriptan. |
| popPK | McConnachie_2023 | irrelevant | 0 | 0 | The study is an in-vitro receptor pharmacology assay for dihydroergotamine with sumatriptan as a comparator, reporting no pharmacokinetic parameters. |
| PD | McConnachie_2023 | not_relevant | 0 | 0 | The paper focuses on the receptor pharmacology of dihydroergotamine (DHE) and only provides a single qualitative screening point for sumatriptan (10 μM) without any dose-response curve or numeric PD parameters. |
| PGx | Mehrotra_2007 | not_relevant | 2 | 5 | The study reports a negative association between 5-HT1B receptor variants and clinical response to sumatriptan, finding no evidence that these variants are major determinants of the drug's effect. |
| PGx | Moore_2002 | not_relevant | 0 | 0 | The study investigates a drug-drug interaction (clarithromycin) rather than a pharmacogenomic effect (gene variant/genotype). |
| PGx | Morse_2020 | not_relevant | 2 | 0 | The study uses mouse knockout models to assess transporter function and does not report human pharmacogenomic effects (genotype-phenotype associations) on sumatriptan PK parameters. |
| PGx | Morse_2021 | not_relevant | 5 | 2 | The paper reports pharmacokinetic changes in Oct1 knockout rats (animal model), not in humans with specific genetic variants, and lacks quantitative effect sizes for human pharmacogenomics. |
| PGx | Morse_2021_2 | not_relevant | 2 | 5 | The paper reports in vitro kinetic parameters (Km, Vmax) for sumatriptan in cell lines, but the in vivo pharmacokinetic data are for proguanil and cycloguanil, not sumatriptan. |
| PGx | Petersen_2023 | not_relevant | 0 | 0 | The study investigates treatment response (clinical outcome) rather than specific pharmacokinetic or pharmacodynamic parameters, and reports no association between CYP3A4 variants and response. |
| PGx | Pöstges_2023 | not_relevant | 0 | 0 | The paper investigates the metabolic pathways of sumatriptan using recombinant enzymes in vitro but does not report pharmacogenomic effects (gene variants) on PK/PD parameters in humans. |
| PGx | Rahman_2024 | not_relevant | 0 | 0 | The study is a preclinical animal model investigating the efficacy of sumatriptan on motion sickness, with no analysis of gene variants or pharmacogenomic effects on PK/PD parameters. |
| PGx | Römer_2021 | not_relevant | 5 | 5 | The study reports that the rs35854239 variant is not associated with significant changes in the pharmacokinetics of sumatriptan. |
| popPK | Schlachter_2026 | irrelevant | 0 | 0 | The study reports population pharmacokinetic parameters for atogepant, not sumatriptan. |
| PGx | Sternieri_2006 | not_relevant | 0 | 0 | The paper is a review of drug-drug interactions and does not report pharmacogenomic effects (gene variants) on sumatriptan PK/PD. |
| popPK | Takahashi_1995 | irrelevant | 0 | 0 | The paper is a pharmacodynamic study on airway smooth muscle tone and receptor characterization, not a pharmacokinetic study, and sumatriptan is used only as a pharmacological probe. |
| PD | Takahashi_1995 | not_relevant | 0 | 0 | The paper reports pharmacological data for 5-HT and its analogs, explicitly stating that sumatriptan was essentially inactive, and does not provide any exposure-response or dose-response parameters for sumatriptan. |
| PGx | Tepper_2001 | not_relevant | 0 | 0 | The paper discusses general safety, drug-drug interactions, and clinical usage guidelines for triptans, but does not report any pharmacogenomic effects (gene variants) on PK or PD parameters. |
| PGx | Tzvetkov_2017 | not_relevant | 0 | 0 | The paper is a review focusing on opioids and anti-migraine drugs generally, and does not report specific pharmacogenomic effects on sumatriptan PK/PD parameters. |
| PGx | Varma_2023 | not_relevant | 2 | 0 | The paper is a general review of organic cation transporters and mentions sumatriptan only as an example of a drug affected by these mechanisms, without reporting specific pharmacogenomic data or effect sizes for sumatriptan. |
| popPK | van_2002 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of contractile responses in isolated arteries, not a pharmacokinetic study reporting disposition parameters for sumatriptan. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-09-21 07:41 UTC</sub>
